Literature DB >> 6787332

Prenatal diagnosis of I-cell disease by measuring altered alpha-mannosidase activity in amniotic fluid.

M Owada, O Nishiya, T Sakiyama, T Kitagawa.   

Abstract

Prenatal diagnoses of I-cell disease were carried out by examination of the amniotic fluid and cultured amniotic cells in four cases of high-risk pregnancy in three different families. Three of the four fetuses were diagnosed as having I-cell disease, on the basis of observation of abnormally increased activity of lysosomal acid hydrolases in the amniotic fluid and their decreased activity in cultured amniotic cells, thus leading to therapeutic abortion. alpha-Mannosidase in the amniotic fluid of the fetuses with I-cell disease exhibited significant alterations in pH profile Km value, thermal stability and isoelectric focusing pattern, compared with the enzyme in normal controls. The results indicate that prenatal diagnosis of I-cell disease may be accomplished by demonstration of altered enzymological characteristics of alpha-mannosidase in the supernatant of amniotic fluid. The significance of the alteration of alpha-mannosidase in the amniotic fluid is not known.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6787332     DOI: 10.1007/BF02312545

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  10 in total

1.  Prenatal diagnosis of I-cell disease.

Authors:  I Matsuda; S Arashima; T Mitsuyama; Y Oka; T Ikeuchi; Y Kaneko; M Ishikawa
Journal:  Humangenetik       Date:  1975-10-20

2.  Prenatal diagnosis and fetal pathology of I-cell disease (mucolipidosis type II).

Authors:  P Aula; J Rapola; S Autio; K Raivio; O Karjalainen
Journal:  J Pediatr       Date:  1975-08       Impact factor: 4.406

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Altered serum alpha-D-mannosidase activity in mucolipidosis II and mucolipidosis III.

Authors:  B C Kress; A L Miller
Journal:  Biochem Biophys Res Commun       Date:  1978-04-14       Impact factor: 3.575

5.  Leroy's l-cell disease: markedly increased activity of plasma acid hydrolases.

Authors:  W R Den Tandt; E Lassila; M Philippart
Journal:  J Lab Clin Med       Date:  1974-03

6.  Lysosomal enzymes of amniotic fluid in relation to gestational age.

Authors:  J Butterworth; D M Broadhead; G R Sutherland; A D Bain
Journal:  Am J Obstet Gynecol       Date:  1974-07-15       Impact factor: 8.661

7.  Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis.

Authors:  J H Glaser; W S Sly
Journal:  J Lab Clin Med       Date:  1973-12

8.  Isoelectric fractionation, analysis, and characterization of ampholytes in natural pH gradients. IV. Further studies on the resolving power in connection with separation of myoglobins.

Authors:  O Vesterberg; H Svensson
Journal:  Acta Chem Scand       Date:  1966

9.  Prenatal diagnosis of mucolipidosis II (I-cell disease).

Authors:  J Gehler; M Cantz; M Stoeckenius; J Spranger
Journal:  Eur J Pediatr       Date:  1976-06-08       Impact factor: 3.183

10.  Elevated activity of lysosomal enzymes in amniotic fluid of a fetus with mucolipidosis II (I-cell disease).

Authors:  F Huijing; R J Warren; A G McLeod
Journal:  Clin Chim Acta       Date:  1973-03-30       Impact factor: 3.786

  10 in total
  2 in total

1.  Five related Lebanese individuals with high plasma lysosomal hydrolases: a new defect in mannose-6-phosphate receptor recognition?

Authors:  D Alexander; G Dudin; F Talj; F Bitar; M Deeb; A Khudr; M Abboud; V M Der Kaloustian
Journal:  Am J Hum Genet       Date:  1984-09       Impact factor: 11.025

2.  Identification of predominant GNPTAB gene mutations in Eastern Chinese patients with mucolipidosis II/III and a prenatal diagnosis of mucolipidosis II.

Authors:  Yu Wang; Jun Ye; Wen-Juan Qiu; Lian-Shu Han; Xiao-Lan Gao; Li-Li Liang; Xue-Fan Gu; Hui-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-06-05       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.